References
- American Psychiatric Association. 2000. Diagnostic and Statistical Manual of Mental Disorders, 4th Text Revision. Washington, DC: American Psychiatric Association.
- Anne WS, Lorraine AL, Howard HR, Jr, Stevin HZ. Ziprasidone: A novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001; 425: 197–201
- Bora E, Gönül AS, Akdeniz F, Vahip S. Neuroleptic malignant-like syndrome induced with low-dose quetiapine treated with electroconvulsive therapy. Eur Psychiatry 2003; 18: 322–323
- Colloberative Working Group. Adverse effects of the atypical antipsychotics. J Clin Psychiatry 1998; 12: 17–22
- Chouinard G, Ross-Chouinard A, Annable L, Jones BD. Extrapyramidal symptom rating scale. Can J Neurol Sci 1980; 7: 233
- Elechi CA. Neuroleptic malignant syndrome complicating tetanus treated with chlorpromazine. Trop Doct 1992; 22: 92–93
- Gray NS. Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson's disease: A diagnostic challenge. Hum Psychopharmacol 2004; 19: 205–207
- Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: A review and critique. Am J Psychiatry 1998; 155: 1113–1116
- Leibold J, Patel V, Hasan RA. Neuroleptic malignant syndrome associated with ziprasidone in an adolescent. Clin Ther 2004; 26: 1105–1108
- Lew TY, Tollefson G. Chlorpromazine-induced neuroleptic malignant syndrome and its response to diazepam. Biol Psychiatry 1983; 18: 1441–1446
- Mahmood T, Warren JP. Neuroleptic malignant syndrome from chlorpromazine: case report. J R Coll Gen Pract 1989; 39: 211
- Rasmussen KG. Risk Factors for neuroleptic malignant syndrome. Am J Psychiatry 1998; 155: 1639–1640
- Sadock BJ, Sadock VA (eds). 2000. Kaplan and Sadock's Comprehensive Textbook of Psychiatry. 7th ed. New York, NY: Lippincott, Williams and Wilkins p 2266.
- Sadock BJ, Sadock VA, editors. 2003. Kaplan and Sadock's synopsis of psychiatry: Behavioral sciences – clinical psychiatry. 9th ed. Philadelphia, PA: Lippincott, Williams and Wilkins. p 998.
- Shad P. Pharmacodynamic and pharmacokinetic factors in a cese of neuroleptic malignant syndrome. J Clin Psychopharmacol 1998; 18: 346–347
- Sing KJ, Ramaekers GM, Van Harten PN. Neuroleptic malignant syndrome and quetiapine. Am J Psychiatry 2002; 159: 149–150